Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Other financing activities (2016 - 2024)

BeOne Medicines (BEIGF) has disclosed Other financing activities for 5 consecutive years, with -$3.0 million as the latest value for Q4 2024.

  • Quarterly Other financing activities changed N/A to -$3.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$3.0 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $4.0 million for FY2019, N/A changed from the prior year.
  • Other financing activities for Q4 2024 was -$3.0 million at BeOne Medicines, down from $4.0 million in the prior quarter.
  • The five-year high for Other financing activities was -$3.0 million in Q4 2024, with the low at -$3.0 million in Q4 2024.